Tumore mammella in stadio iniziale: ribociclib in adiuvante riduce di un quarto rischio di recidiva

The anticancer drug ribociclib, in combination with endocrine therapy, compared to endocrine therapy alone, reduces the risk of recurrence by 25.2% in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, early-stage breast cancer, stage II and III. These data come from the pivotal Phase III NATALEE study presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago. We discussed the study with Fabio Puglisi, Director of the Department of Medical Oncology at the IRCCS CRO in Aviano, and Full Professor and Director of the School of Specialization in Medical Oncology at the University of Udine.